Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

OBJECTIVES: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kearsley-Fleet, Lianne, Davies, Rebecca, De Cock, Diederik, Watson, Kath D, Lunt, Mark, Buch, Maya H, Isaacs, John D, Hyrich, Kimme L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161665/
https://www.ncbi.nlm.nih.gov/pubmed/29980575
http://dx.doi.org/10.1136/annrheumdis-2018-213378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161665/
https://www.ncbi.nlm.nih.gov/pubmed/29980575
http://dx.doi.org/10.1136/annrheumdis-2018-213378

Ejemplares similares